Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life to Participate in the TD Cowen 44th Annual Health Care Conference
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Kezar Life to Present at the 6th Annual Evercore ISI HealthCONx Conference
Kezar Life Sciences Reports Third Quarter 2023 Financial Results
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer